HTRF® Ligand Binding Assay for the Chemokine Receptor CXCR4

Authors: Wendy Goodrich, Gary Prescott, Peter Banks, BioTek Instruments, Inc., Winooski, Vermont, USA; François Degorce, Cisbio Bioassays, Bagnols-sur-Cèze, France; Nicolas Pierre, Cisbio US, Bedford, Massachusetts, USA

Abstract

The chemokine receptor CXCR4 has multiple critical functions in normal physiologies including embryonic development of the cardiovascular, hemopoietic and central nervous systems. It has also been implicated in disease pathologies such as HIV infection, cancer metastasis, leukemia progression and rheumatoid arthritis, and is fueling the search for small molecule CXCR4 antagonists as a means for intervention1. Here we demonstrate the suitability of the Tag-lite HTRF® technology for CXCR4 ligand binding assays for high throughput screening applications. Automated assay performance and pharmacology will be presented.

Precision XS, MultiFlo and Synergy H1